Atossa Therapeutics (ATOS) Gross Margin (2011 - 2015)
Atossa Therapeutics (ATOS) posted quarterly Gross Margin of 1159.5% for Q4 2015, up 105950.0% year-over-year from N/an in Q4 2014, and up 1059.5% quarter-over-quarter from 100.0% in Q4 2014.
Atossa Therapeutics (ATOS) Gross Margin (2011 - 2015) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Gross Margin for 5 consecutive years, with 1159.5% the latest figure, recorded in Q4 2015.
- In Q4 2015, Gross Margin rose 105950.0% year-over-year to 1159.5%; the TTM figure through Sep 2016 stood at 1159.5% (down 1585307.0% YoY), while the FY2015 annual figure was 112854.49%, up 11275449.0% from the prior year.
- Gross Margin improved to 1159.5% in Q4 2015 per ATOS's latest filing, from 100.0% in the prior quarter.
- Across five years, Gross Margin topped out at 6569.89% in Q2 2012 and bottomed at 6379.33% in Q4 2011.
- Historically, Gross Margin has averaged 312.38% across 5 years, with a median of 100.0% in 2014.
- Annual changes were most pronounced in 2012 — Gross Margin jumped 647348 bps — and 2013, when it sank 648364 bps.
- Atossa Therapeutics' Gross Margin stood at 6379.33% in 2011, then surged by 101 bps to 94.15% in 2012, then plunged by 61 bps to 36.94% in 2013, then surged by 171 bps to 100.0% in 2014, then surged by 1059 bps to 1159.5% in 2015.
- Business Quant data shows ATOS's Gross Margin at 1159.5% in Q4 2015, 100.0% in Q4 2014, and 100.0% in Q3 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 76.90% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 63.27% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 84.20% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Atossa Therapeutics | 22.63 Mn | 22.63 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 1,159.50% |
| Dec 31, 2014 | 100.00% |
| Sep 30, 2014 | 100.00% |
| Jun 30, 2014 | 100.00% |
| Mar 31, 2014 | 100.00% |
| Dec 31, 2013 | 36.94% |
| Sep 30, 2013 | 70.18% |
| Jun 30, 2013 | 86.25% |
| Mar 31, 2013 | 864.63% |
| Dec 31, 2012 | 94.15% |
| Sep 30, 2012 | 85.72% |
| Jun 30, 2012 | 6,569.89% |
| Mar 31, 2012 | 1,385.45% |
| Dec 31, 2011 | -6,379.33% |